|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
|
25227799 |
2014 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Kaplan-Meier survival curves indicated that OBR and HSP90 expression were associated with reduced overall survival in breast cancer patients (HR = 1.9/p = 0.022; HR = 2.2/p = 0.00017, respectively).
|
26556856 |
2016 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Hsp90 can constitute as much as 5% of total protein in transformed cells and increased levels of heat-shock activation correlate with poor prognosis in breast cancer.
|
26916007 |
2016 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
It regulates the stability and function of numerous client proteins that are frequently upregulated and/or mutated in cancer cells, therefore, making Hsp90 inhibition a promising therapeutic strategy for the development of new efficacious drugs to treat breast cancer.
|
31493740 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
This study used multiple in vitro assays to determine if OPN levels could predict breast cancer cell sensitivity to Hsp90 and/or Src kinase inhibitors.
|
21795853 |
2011 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Here we used D,L-lactic-co-glycolic acid-polyethylene glycol-17-dimethylaminoethylamino-17-demethoxy geldanamycin (PLGA-PEG-17DMAG) complexes and free 17-DMAG to inhibit the expression of HSP90 gene in the T47D breast cancer cell line.
|
27268613 |
2016 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
|
31522240 |
2020 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Together, we discovered that HSP90AB1 is USP22-dependent and that cooperative targeting of USP22 and HSP90 may provide an effective approach to the treatment of colorectal and breast cancer.
|
31801945 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Adopting a pathophysiological perspective, this systematic review aims to synthesize the evidence examining the association between Hsp70/Hsp90 expression and breast cancer prognosis, as well as prognosis-related clinicopathological indices.
|
29491085 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
|
29437790 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
|
28051275 |
2016 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Translocase of the outer mitochondrial membrane 34 (Tomm34) is a cochaperone of both Hsp70 and Hsp90 that was found to be overexpressed in colorectal, hepatocellular, lung and breast carcinomas.
|
30917858 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
In the present study, the role of Hsp90 in human breast cancer MCF-7 cells was examined by stably silencing Hsp90 gene expression with an Hsp90-silencing vector (Hsp90-shRNA).
|
22521890 |
2012 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Inhibiting HER2 pharmacologically by Lapatinib (a dual HER2/epidermal growth factor receptor inhibitor) or CP724.714 (a specific HER2 inhibitor), or by knockdown via siRNA leads to inhibition of phosphoactivated Ser326 HSF1, and subsequently blocks the activity of the HSP90 chaperone machinery in HER2-overexpressing breast cancer lines.
|
24384723 |
2014 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
In the present study, we further demonstrated that 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an inhibitor of Hsp90, could suppress the self-renewal of BCSCs by downregulating B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a polycomb family member with oncogenic activity in breast cancer.
|
28914785 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
In conclusion, our findings, identifying for the first time leptin/leptin receptor/Hsp90 axis as an important regulator of exosome generation in mammary carcinoma cells, suggest that targeting this signaling pathway might represent a novel therapeutic strategy to impair exosome secretion and interrupt the dangerous cell-to-cell communication in breast cancer.
|
31336913 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
We have developed a non-destructive strategy using HS-27, a fluorescently-tethered Hsp90 inhibitor, to assay surface Hsp90 expression on intact tissue specimens and validated our approach in clinical samples from breast cancer patients across estrogen receptor positive, Her2-overexpressing, and triple negative receptor subtypes.
|
30837677 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells.
|
24705874 |
2014 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
High-level expression of HSP90AA1 and HSP90AB1, two cytoplasmic HSP90 isoforms, was driven by chromosome coding region amplifications and were independent factors that led to death from breast cancer among patients with triple-negative (TNBC) and HER2-/ER+ subtypes, respectively.
|
22510516 |
2012 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
|
11489796 |
2001 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
These data suggest that (1) hsp90, as for all steroid receptors, acts as a molecular chaperone for ERbeta; (2) ER-ligands (except tamoxifen), hsp90- and immunophilin-ligands (except FK506) target the two ER subtypes to a proteasome-mediated proteolysis via different signalling pathways; (3) hsp90- and immunophilin-ligands Rapa and CsA, alone or in association with anti-estrogens such as RU, may constitute a potential therapeutic strategy for breast cancer treatment.
|
15862952 |
2005 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
A subset of DNA repair proteins such as Breast cancer gene 1 (BRCA1), BRCA2 and RecA homolog (RAD51) are client proteins of heat shock protein 90 (Hsp90).
|
28111726 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
A novel role for DYX1C1, a chaperone protein for both Hsp70 and Hsp90, in breast cancer.
|
19277710 |
2009 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Guided by our previous work in pathogenic fungi, in which very modest HSP90 inhibition impairs resistance to mechanistically diverse antifungals, we examined the effect of similarly modest HSP90 inhibition on the emergence of resistance to antiestrogens in breast cancer models.
|
25489079 |
2014 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Downregulation of Bcl-2 and Bcl-xL, upregulation of Bax, cleavage of caspase-9 and poly (ADP-ribose) polymerase (PARP), and degradation of the breast cancer-related Hsp90 client proteins human epidermal growth factor receptor-2 (HER2), Akt, Raf-1, and nuclear factor kappa-B kinase (IKK) were observed in SNX-2112 treated cells by Western blot assay.
|
21821931 |
2011 |